US3919051A - Biological analyzer and method - Google Patents

Biological analyzer and method Download PDF

Info

Publication number
US3919051A
US3919051A US487709A US48770974A US3919051A US 3919051 A US3919051 A US 3919051A US 487709 A US487709 A US 487709A US 48770974 A US48770974 A US 48770974A US 3919051 A US3919051 A US 3919051A
Authority
US
United States
Prior art keywords
solution
membrane
enzyme
concentration
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US487709A
Inventor
Robert B Koch
Leroy D Nelson
Gerald D Rork
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Honeywell Inc
Original Assignee
Honeywell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Honeywell Inc filed Critical Honeywell Inc
Priority to US487709A priority Critical patent/US3919051A/en
Application granted granted Critical
Publication of US3919051A publication Critical patent/US3919051A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483Physical analysis of biological material
    • G01N33/487Physical analysis of biological material of liquid biological material
    • G01N33/49Blood
    • G01N33/4915Blood using flow cells

Definitions

  • a continuous flow method and apparatus for the de termination of glucose in a biological fluid h the ox gen depletion method is provided.
  • the biological fluid sample. along with a carrier solution. are combined and introduced into a chamber containing gelimmobilized glucose oxidase.
  • the mixture is caused to Hon sequentially through the immobilized glucose oxidase and a connecting passage the outlet of which is disposed such that the fluid impinges on an o ⁇ ⁇ gcnpermeable membrane where the oxygen dillusing therethrough drains sensed electrochemically
  • the ctfluent solution drians and the system is regenerated b Flushing with a quantity of the reagent solution.
  • the glucose oxidase is immobilized in a manner which al lows many tests to be run without an significant loss of em ⁇ me thereby accomplishing a considerable cost reduction in the tests.
  • FIG.I ACETATE BUFFER SUPPLY RESERVOIR r33 I w 32 CONSTANT OXYGEN HEAD SUPPLY ANALYZER DISPLAY DEVICE
  • the present invention relates to the field of testing samples of biological fluids for specific components and, in particular, the determination of glucose in such fluids as blood by the oxygen-depletion method.
  • the enzyme electrode method is essentially a batch-type operation wherein residual products of one reaction may interfere with readings taken for subsequent tests unless special cleaning steps are utilized to remove any unreacted components and products of a previous reaction before the next test is made. Also, an additional membrane normally must be placed over the immobilized enzyme gel to prevent loss of the enzyme from the gel into the reacting solution.
  • the present invention contemplates a method and apparatus for determining the concentration of a component in a biological sample. ie the determination of glucose in a fluid such as blood serum. wherein the measured sample is combined with an amount of carrier solution and introduced into a flow-through reaction chamber such as a column. for example. containing an amount of immobilized glucose oxidase where the desired reaction is catalyzed and takes place. The solution which is then substantially completely re acted then continues to flow. while still in the closed system. and is caused to impinge on a gas-permeable membrane opposite a measuring electrode in a manner which facilitates oxygen diffusion therethrough. and at the same time. by washing thereover continuously cleanses the membrane.
  • the effluent containing the reacted sample is then discarded via a drain.
  • the oxygen tension is measured electrochemically through the membrane during the time which the reacted sample impinges on the opposite side of the membrane allowing the dissolved oxygen to diffuse thercthrough.
  • the system is then cleansed by allowing an additional amount ofthe reagent solution to flow through the system returning the oxygen reading to a stable base line.
  • the flowthrough system of the present invention may be one utilizing a constant head type pump or one operated by gravity.
  • the flow rate may be conveniently controlled by selection of the size and length of the conduit and column components of the flow system such that the sample is completely reacted by the time the oxygen is measured at the electrode and assuring that sufficient oxygen-containing carrier solution is supplied to completely react the glucose in each sample.
  • no built in delays or other complicated electronics are required to measure the output of the system of the invention to allow for the time ofreaction or other variable as is required in batch wise systems in which the measurement is made in the same chamber as the reaction.
  • a point other than the end point of the reaction may be selected and the flow standardized to obtain reproducible readings at that point.
  • the temperature of the system may be controlled as the rate of the enzyme-catalyzed reaction is somewhat temperature dependent.
  • FIG. I is an illustration, partially in diagramatic form and partially in section. depicting the apparatus of the invention generally and FIG. 2 is an enlarged view ofa portion of FIG. I illustrating the measurement system of the preferred embodiment.
  • FIG. I is a general. overall illustration ofthe apparatus of the invention. For purposes of clarity some ofthe figure is shown in section. and for simplification. a portion is illustrated in block form.
  • a carrier solution in which the reaction takes place and also which serves as a cleansing solution for the entire system is supplied from a supply reservoir to a constant head supply tank ll by a conventional method such as pumping into the constant head supply tank or by overflow from a separate weir system in a well known manner.
  • the carrier solution is supplied from the constant head supply to the remainder of the flow system of the apparatus as by a conduit 12 having a flow shutoff valve 13.
  • a measured sample of biological fluid to be analyzed is introduced into the system from a separate injection port 14 normally from a graduated syringe.
  • a septum membrane 16 serves as a closure member for the bottom of the injection port.
  • the sample then is introduced along with the carrier solution at 17 just above a reaction column 18.
  • One advantage of the instrument of the present invention lies in the fact that very small samples may be used in the analysis.
  • a typical sample size is about 50 microliters.
  • the shutoff valve 13 may be left continuously in the open position.
  • the flow ofcarrier solution required to be maintained in the system for the consecutive analysis of 50 microliter samples is only about 1.0 milliliter per minute and such continuous flow will not consume significant quantities of the carrier solution.
  • the volumes of the rest of the system components are sized commensurate with this flowrate.
  • the combined or test solution then passes through a porous plug 19, which may be made ofa glass frit material or may be a fine metal screen or approximately 100 mesh.
  • the reaction column [8 contains an amount of enzyme immobilized in a finely divided gel matrix.
  • a further porous plug 20 much like the plug 19 closes the bottom of the column and. while allowing free flow of the test solution therethrough prevents any loss of the enzyme-containing gel from the column.
  • the test solution flows from the bottom of the column through another conduit 21 to a chamber 22 where the final oxygen content of the solution is measured.
  • the effluent is continually discharged through a drain 23.
  • the conduit 21 is sized and the downstream terminal opening thereof is disposed such that the test solution enters the chamber 22 in a manner which causes it to impinge upon a membrane 24 at an angle and to strike the membrane with a relatively high velocity.
  • the test solution at the same time. circulates about and cleanses the chamber prior to flowing out the drain 23. This configuration is discussed in greater detail in relation to FIG. 2, below.
  • the membrane 24 is disposed across the bottom of an electrochemical cell 25 containing an oxygen sensitive electrode 26 and defines a barrier separating the internal cell electrolyte from the external environment of chamber 22.
  • a liquid-tight seal is provided about the perphery of the interface between the electrochemical cell 25 and chamber 22 (which is formed as a hollowed portion of base member 27) by conventional means which may include an O-ring 28 held in a sealing position by a retaining member 29 and screws 30 which secure the electrochemical cell 25 to base member 27.
  • the electrochemical cell 25 may also be threadihly attached within the retaining member 29 as at 31 to facilitate its separate removal.
  • the desired sealing compression on O-ring 28. in that embodiment. is accomplished by screwing down cell 25.
  • the membrane 24 is a non-conducting material which is impervious to the passage of either electrolyte in the electrochemical cell 25 or the solution in chamber 22 and one which does not chemically react with either solution. It is highly oxygen permeable. however. and. as such. does allow the passage ofoxygen from the solution in the chamber 22 into the cell 26.
  • One material which has successfully been used for the membrane is a film of a tetrafluroethylene polymer (such as 0.5 to l mil Emflon. UTF-lO(). manufactured by Pallflex Products Corporation of Putnam. Conn.].
  • the electrode 26 is positioned preferrably directly opposite the point of impingement of the solution emminating from the conduit 21 to reduce the lag time in making the oxygen measurementv
  • the combination of the relatively high velocity impingement of the solution and the electrode location results in a considerably faster response by the electrode 26.
  • Leads 32 convey the signal from the electrochemical cell 25 to a conventional oxygen analyzer shown in block at 33 and the processed signals are then fed to a display device at 34.
  • the electrochemical oxygen detection system is also a conventional system which utilizes an electrode for determining dissolved oxygen such as a model No. 39553 manufactured by Beckman Instruments. Inc. of Fullerton. Calif.
  • the oxygen analyzer 33 and display device 34, downstream electrically from the oxygen detecting electrochemical system may also be any con ventional instrumentation connected in a well known manner.
  • the display device 34 may be calibrated to read the percentage of glucose in the sample directly if desired.
  • Conduit means l2, l7 and 21 may be glass tubing or any such conduit means conventional to analytical apparatus. The only criteria being that they not affect or be affected by the solutions passed therethrough in the preferred embodiment.
  • the conduit 21 along with drain 23 are formed by conventional hollowed fittings with the exception of those located in the block 27, discussed below. Fittings are normally made ofa relatively inert material such as teflon or nylon and the various components are held together by screwed compression fittings as at 35, for example.
  • the reaction column for containing the immobilized enzyme may be a conventional glass tubing column or one of compatable plastic such as an acrylic.
  • the gel utilized for entrapping the enzyme is a specially prepared crosslinked acrylamide gel in which the cross linking agent is normally N. N-methylenebisacrylamide and in which the ratio of acrylamide to cross linking agent is extremely high. normally from about 45:1 to about 55:1. This high ratio gel yields a much improved enzyme entrapping latice in which the leaching of the glucose oxidase molecules is greatly reduced.
  • the preparation of the gel entrapping the glucose oxidase enzyme is described more fully in the copending application of Koch et al. Ser. No. 425.043 (which is a division of Ser. No. 276,630 filed July 3l I972, now abandoned) and assigned to the same assignee as the present application.
  • the base member 27 contains hollowed chamber 22 into which the conduit 21 feeds and out of which the drain 23 drains the fluid.
  • the downstream end of the conduit 21 is disposed such that the fluid. as indicated by the arrows in the preferred embodiment is directed in a direction normal to the membrane 24 such that it impinges directly on that membrane.
  • the electrode 26 is disposed. in the preferred embodiment. directly opposite the membrane lined up with the impinging stream from the conduit 21.
  • this arrangement has several advantages. First. by causing the flowing stream to impinge directly on the membrane opposite the electrode 26, oxygen depletion in the solution in the immediate vicinity of the electrode 26 associated with the consumption of oxygen by the electrode which results in possible measurement error is prevented by the continual flow of the solution. Second, the constant draining of the system also ensures that the fluid immediately in front of the membrane is constantly being changed and the entire chamber 22 is constantly being washed by new fluid. Thus, the arrangement both avoids incorrect reading of the oxygen content due to oxygen consumption from the fluid by the electrode and avoids the possibility of incorrect readings being caused from residual fluid in the chamber from previous samples.
  • the outlet hole 21a of the conduit 21 is normally made very small to permit the operation of the entire system at a lower flow rate and greatly reduce the required sample size.
  • the configuration of the flow system in the chamber 22 is also quite important at this reduced flow rate.
  • the normal flow rate through the entire system in the preferred embodiment is approximately 1 ml per minute and the required sample size at this flow rate is approximately 50 ul per minute per sample.
  • this extremely low flow rate not only conserves the carrier solution and greatly reduces the size of the required sample but also allows the system to be continually operated with valve 13 open so that the chamber 22 and membrane 24 can be continuously cleansed between tests thus returning the oxygen measurement quickly to a stable baseline between the injection of consecutive samples.
  • the base 27 is normally made of a block of compatable polymer material such as an acrylic plastic which can be drilled or molded to the appropriate configuration for the system. Because of the small volume of sample and carrier solution required for each test, the entire system may be conveniently located within a small cabinet or portable analytical device.
  • the present invention presents a simple, convenient and economical analytical instrument for the analysis of glucose in biological fluids which combines simplicity of design with speed and accuracy in glucose measurement in such fluids.
  • the carrier solution in operation, continuously flows through the system and the biological fluid sample containing approximately 50 ii] is injected into the flowing carrier solution through the septum 16.
  • the carrier solution is normally an 0.1 M aqueous solution of sodium acetate buffer.
  • the combined solution then flows by gravity through the immobilized enzyme column in which the molecules of solution are free to contact the immobilized enzyme and the above-mentioned catalyzed reaction then takes place as the solution flows through the column.
  • the reaction is essentially complete at the time the solution exits from the bottom of the column through the screen or frit 20 and passes via the conduit 2
  • a flow-through chemical analysis apparatus for determining the concentration of a component of interest in a sample wherein the detection of the concentration of an indicating species following an enzyme'catalyzed reaction is indicative of the concentration of the component of interest in the sample, said apparatus com 7 prising:
  • a first chamber for containing an amount of an immohilized enzyme disposed therein in a manner which allows free contact between said enzyme and a solution flowing therethrough to thereby catalyze said enzyme-catalyzed reaction;
  • sensor means for detecting said indicating species in said solution.
  • said sensor means being separated from the said second chamber by a membrane per meable to said indicating species;
  • flow means connecting the outlet of said first chamher with said second chamber. in a manner which causes said solution to impinge on said membrane at an angle with said membrane;
  • drain means for removing said solution after contacting said membrane
  • transducing means for transducing said output into one indicative of the concentration of the component in the sample sought to be determined.
  • said means for supplying said sample is an injection port wherein an accurately determined amount of such sample may be injected into said solution.
  • said senor is an electrochemical detector and said indicating species to be detected is a dissolved gas.
  • said detector having a sensoring electrode disposed opposite and in close proximity to said membrane.

Abstract

A continuous flow method and apparatus for the determination of glucose in a biological fluid by the oxygen depletion method is provided. The biological fluid sample, along with a carrier solution, are combined and introduced into a chamber containing gel-immobilized glucose oxidase. The mixture is caused to flow sequentially through the immobilized glucose oxidase and a connecting passage the outlet of which is disposed such that the fluid impinges on an oxygen-permeable membrane where the oxygen diffusing therethrough drains sensed electrochemically. The effluent solution drians and the system is regenerated by flushing with a quantity of the reagent solution. The glucose oxidase is immobilized in a manner which allows many tests to be run without any significant loss of enzyme thereby accomplishing a considerable cost reduction in the tests.

Description

United States Patent Koch et al.
ACETATE BUFFER SUPPLY RESERVOIR CONSTANT HEAD lll] 3,919,051
Nov. 11,1975
l 5 1 ABSTRACT A continuous flow method and apparatus for the de termination of glucose in a biological fluid h the ox gen depletion method is provided. The biological fluid sample. along with a carrier solution. are combined and introduced into a chamber containing gelimmobilized glucose oxidase. The mixture is caused to Hon sequentially through the immobilized glucose oxidase and a connecting passage the outlet of which is disposed such that the fluid impinges on an o\ \gcnpermeable membrane where the oxygen dillusing therethrough drains sensed electrochemically The ctfluent solution drians and the system is regenerated b Flushing with a quantity of the reagent solution. The glucose oxidase is immobilized in a manner which al lows many tests to be run without an significant loss of em} me thereby accomplishing a considerable cost reduction in the tests.
ll Claims. 2 Drawing Figures OXYGEN ANALYZER DISPLAY DEVICE US. Patent Nov. 11, 1975 Sheet 1 of 2 3,919,051
ACETATE BUFFER SUPPLY RESERVOIR r33 I w 32 CONSTANT OXYGEN HEAD SUPPLY ANALYZER DISPLAY DEVICE FIG.I
US. Patent Nov. 11, 1975 Sheet 2 of 2 BIOLOGICAL ANALYZER AND METHOD BACKGROUND OF THE INVENTION l. Field of the Invention The present invention relates to the field of testing samples of biological fluids for specific components and, in particular, the determination of glucose in such fluids as blood by the oxygen-depletion method.
2. Description of the Prior Art The use of enzymes in the determination of various components in biological fluids is gaining rapidly as an analytical technique. This technique generally involves the measurement of the concentration of one or more products, the depletion of one or more reactants or the change in solution condition following an enzyme-catalyzed reaction in which a specific enzyme is utilized to catalyze a known reaction. An example of this is found in the determination of glucose in blood, urine or other biological fluids. In the presence of the enzyme glucose oxidase (G) the glucose in the biological fluid reacts with oxygen in the following manner:
Glucose+O H O i'kGluconic acid H O When this reaction takes place with an excess of oxygen over that required to oxidize all the glucose in the biological sample, there is a linear relationship between the depletion of oxygen and the glucose concentration in the biological sample. Thus, if the oxygen tension is measured after the reaction and compared with a known or measured value before the reaction the exact amount of glucose in the biological cample may be readily determined.
One prior art device for measuring oxygen depletion due to the above reaction is illustrated and described in US. Pat. No. 3,542,662. That reference discloses an electrochemical transducer in the form of an oxygen measuring electrode in combination with a polyacrylamide gel covering which contains an amount of immobilized glucose oxidase therein. The electrode is then immersed in a solution containing the biological fluid to be analyzed wherein the reactants diffuse into the gel matrix where the catalyzed reaction takes place and the oxygen tension is then measured through the membrane electrochemically.
It is also known in the prior art that it is advantageous to flow a solution in which a dissolved gas such as oxygen is to be measured past the membrane-covered electrode to increase the sensitivity and response of the electrode to the dissolved gas. Such a technique is described in an article by John T. Penniston An Extremely Rapid Burst of Respiration upon Aeration of Mitochondria: Measurement of Oxygen Tension with lOmsec Time Resolution"; Archives of Biochemistry and Biophysics I50, 556565 (1972).
Although the prior art devices have utilized techniques which have advanced the state of enzymatic analysis, there has long been a need for more efficient and automated systems. The enzyme electrode method is essentially a batch-type operation wherein residual products of one reaction may interfere with readings taken for subsequent tests unless special cleaning steps are utilized to remove any unreacted components and products of a previous reaction before the next test is made. Also, an additional membrane normally must be placed over the immobilized enzyme gel to prevent loss of the enzyme from the gel into the reacting solution.
SUMMARY OF THE INVENTION According to the present invention. there is provided a method and apparatus for chemical analysis which combines an improved enzyme-catalyzed reaction system with an improved oxygen sensing technique in a flow-through analytical system. By means of the pres ent invention a large number ofdeterminations may be made without replacing either the enzyme or utilizing a special cleaning procedure for the system,
Briefly, the present invention contemplates a method and apparatus for determining the concentration of a component in a biological sample. ie the determination of glucose in a fluid such as blood serum. wherein the measured sample is combined with an amount of carrier solution and introduced into a flow-through reaction chamber such as a column. for example. containing an amount of immobilized glucose oxidase where the desired reaction is catalyzed and takes place. The solution which is then substantially completely re acted then continues to flow. while still in the closed system. and is caused to impinge on a gas-permeable membrane opposite a measuring electrode in a manner which facilitates oxygen diffusion therethrough. and at the same time. by washing thereover continuously cleanses the membrane. The effluent containing the reacted sample is then discarded via a drain. The oxygen tension is measured electrochemically through the membrane during the time which the reacted sample impinges on the opposite side of the membrane allowing the dissolved oxygen to diffuse thercthrough. The system is then cleansed by allowing an additional amount ofthe reagent solution to flow through the system returning the oxygen reading to a stable base line.
The flowthrough system of the present invention may be one utilizing a constant head type pump or one operated by gravity. The flow rate may be conveniently controlled by selection of the size and length of the conduit and column components of the flow system such that the sample is completely reacted by the time the oxygen is measured at the electrode and assuring that sufficient oxygen-containing carrier solution is supplied to completely react the glucose in each sample. Thus, no built in delays or other complicated electronics are required to measure the output of the system of the invention to allow for the time ofreaction or other variable as is required in batch wise systems in which the measurement is made in the same chamber as the reaction.
Of course. if desired, a point other than the end point of the reaction may be selected and the flow standardized to obtain reproducible readings at that point.
If required the temperature of the system may be controlled as the rate of the enzyme-catalyzed reaction is somewhat temperature dependent.
BRIEF DESCRIPTION OF THE DRAWINGS In the drawings, wherein like numbers are used to denote like parts throughout the same:
FIG. I is an illustration, partially in diagramatic form and partially in section. depicting the apparatus of the invention generally and FIG. 2 is an enlarged view ofa portion of FIG. I illustrating the measurement system of the preferred embodiment.
DESCRIPTION OF THE PREFERRED EMBODIMENT FIG. I is a general. overall illustration ofthe apparatus of the invention. For purposes of clarity some ofthe figure is shown in section. and for simplification. a portion is illustrated in block form. A carrier solution in which the reaction takes place and also which serves as a cleansing solution for the entire system is supplied from a supply reservoir to a constant head supply tank ll by a conventional method such as pumping into the constant head supply tank or by overflow from a separate weir system in a well known manner. The carrier solution is supplied from the constant head supply to the remainder of the flow system of the apparatus as by a conduit 12 having a flow shutoff valve 13.
A measured sample of biological fluid to be analyzed is introduced into the system from a separate injection port 14 normally from a graduated syringe. A septum membrane 16 serves as a closure member for the bottom of the injection port. The sample then is introduced along with the carrier solution at 17 just above a reaction column 18.
One advantage of the instrument of the present invention lies in the fact that very small samples may be used in the analysis. A typical sample size is about 50 microliters. During the duration of operating the instrumerit. the shutoff valve 13 may be left continuously in the open position. The flow ofcarrier solution required to be maintained in the system for the consecutive analysis of 50 microliter samples is only about 1.0 milliliter per minute and such continuous flow will not consume significant quantities of the carrier solution. Of course. the volumes of the rest of the system components are sized commensurate with this flowrate.
The combined or test solution then passes through a porous plug 19, which may be made ofa glass frit material or may be a fine metal screen or approximately 100 mesh. The reaction column [8 contains an amount of enzyme immobilized in a finely divided gel matrix. A further porous plug 20 much like the plug 19 closes the bottom of the column and. while allowing free flow of the test solution therethrough prevents any loss of the enzyme-containing gel from the column. The test solution flows from the bottom of the column through another conduit 21 to a chamber 22 where the final oxygen content of the solution is measured. The effluent is continually discharged through a drain 23.
The conduit 21 is sized and the downstream terminal opening thereof is disposed such that the test solution enters the chamber 22 in a manner which causes it to impinge upon a membrane 24 at an angle and to strike the membrane with a relatively high velocity. The test solution. at the same time. circulates about and cleanses the chamber prior to flowing out the drain 23. This configuration is discussed in greater detail in relation to FIG. 2, below.
The membrane 24 is disposed across the bottom of an electrochemical cell 25 containing an oxygen sensitive electrode 26 and defines a barrier separating the internal cell electrolyte from the external environment of chamber 22. A liquid-tight seal is provided about the perphery of the interface between the electrochemical cell 25 and chamber 22 (which is formed as a hollowed portion of base member 27) by conventional means which may include an O-ring 28 held in a sealing position by a retaining member 29 and screws 30 which secure the electrochemical cell 25 to base member 27.
4 The electrochemical cell 25 may also be threadihly attached within the retaining member 29 as at 31 to facilitate its separate removal. The desired sealing compression on O-ring 28. in that embodiment. is accomplished by screwing down cell 25.
The membrane 24 is a non-conducting material which is impervious to the passage of either electrolyte in the electrochemical cell 25 or the solution in chamber 22 and one which does not chemically react with either solution. It is highly oxygen permeable. however. and. as such. does allow the passage ofoxygen from the solution in the chamber 22 into the cell 26. One material which has successfully been used for the membrane is a film of a tetrafluroethylene polymer (such as 0.5 to l mil Emflon. UTF-lO(). manufactured by Pallflex Products Corporation of Putnam. Conn.]. The electrode 26 is positioned preferrably directly opposite the point of impingement of the solution emminating from the conduit 21 to reduce the lag time in making the oxygen measurementv The combination of the relatively high velocity impingement of the solution and the electrode location results in a considerably faster response by the electrode 26.
Leads 32 convey the signal from the electrochemical cell 25 to a conventional oxygen analyzer shown in block at 33 and the processed signals are then fed to a display device at 34.
The electrochemical oxygen detection system is also a conventional system which utilizes an electrode for determining dissolved oxygen such as a model No. 39553 manufactured by Beckman Instruments. Inc. of Fullerton. Calif. The oxygen analyzer 33 and display device 34, downstream electrically from the oxygen detecting electrochemical system may also be any con ventional instrumentation connected in a well known manner. The display device 34 may be calibrated to read the percentage of glucose in the sample directly if desired.
Conduit means l2, l7 and 21 may be glass tubing or any such conduit means conventional to analytical apparatus. The only criteria being that they not affect or be affected by the solutions passed therethrough in the preferred embodiment. The conduit 21 along with drain 23 are formed by conventional hollowed fittings with the exception of those located in the block 27, discussed below. Fittings are normally made ofa relatively inert material such as teflon or nylon and the various components are held together by screwed compression fittings as at 35, for example.
The reaction column for containing the immobilized enzyme may be a conventional glass tubing column or one of compatable plastic such as an acrylic. The gel utilized for entrapping the enzyme is a specially prepared crosslinked acrylamide gel in which the cross linking agent is normally N. N-methylenebisacrylamide and in which the ratio of acrylamide to cross linking agent is extremely high. normally from about 45:1 to about 55:1. This high ratio gel yields a much improved enzyme entrapping latice in which the leaching of the glucose oxidase molecules is greatly reduced. The preparation of the gel entrapping the glucose oxidase enzyme is described more fully in the copending application of Koch et al. Ser. No. 425.043 (which is a division of Ser. No. 276,630 filed July 3l I972, now abandoned) and assigned to the same assignee as the present application.
As discussed above. the base member 27 contains hollowed chamber 22 into which the conduit 21 feeds and out of which the drain 23 drains the fluid. The downstream end of the conduit 21 is disposed such that the fluid. as indicated by the arrows in the preferred embodiment is directed in a direction normal to the membrane 24 such that it impinges directly on that membrane. The electrode 26 is disposed. in the preferred embodiment. directly opposite the membrane lined up with the impinging stream from the conduit 21.
As briefly mentioned above. this arrangement has several advantages. First. by causing the flowing stream to impinge directly on the membrane opposite the electrode 26, oxygen depletion in the solution in the immediate vicinity of the electrode 26 associated with the consumption of oxygen by the electrode which results in possible measurement error is prevented by the continual flow of the solution. Second, the constant draining of the system also ensures that the fluid immediately in front of the membrane is constantly being changed and the entire chamber 22 is constantly being washed by new fluid. Thus, the arrangement both avoids incorrect reading of the oxygen content due to oxygen consumption from the fluid by the electrode and avoids the possibility of incorrect readings being caused from residual fluid in the chamber from previous samples. The outlet hole 21a of the conduit 21 is normally made very small to permit the operation of the entire system at a lower flow rate and greatly reduce the required sample size. In this respect the configuration of the flow system in the chamber 22 is also quite important at this reduced flow rate. For an outlet hole 21a of approximately 0.18 cm. in diameter, the normal flow rate through the entire system in the preferred embodiment is approximately 1 ml per minute and the required sample size at this flow rate is approximately 50 ul per minute per sample. As explained above, this extremely low flow rate not only conserves the carrier solution and greatly reduces the size of the required sample but also allows the system to be continually operated with valve 13 open so that the chamber 22 and membrane 24 can be continuously cleansed between tests thus returning the oxygen measurement quickly to a stable baseline between the injection of consecutive samples.
The base 27 is normally made ofa block of compatable polymer material such as an acrylic plastic which can be drilled or molded to the appropriate configuration for the system. Because of the small volume of sample and carrier solution required for each test, the entire system may be conveniently located within a small cabinet or portable analytical device. Thus, the present invention presents a simple, convenient and economical analytical instrument for the analysis of glucose in biological fluids which combines simplicity of design with speed and accuracy in glucose measurement in such fluids.
In operation, the carrier solution, as mentioned above, continuously flows through the system and the biological fluid sample containing approximately 50 ii] is injected into the flowing carrier solution through the septum 16. The carrier solution is normally an 0.1 M aqueous solution of sodium acetate buffer. The combined solution then flows by gravity through the immobilized enzyme column in which the molecules of solution are free to contact the immobilized enzyme and the above-mentioned catalyzed reaction then takes place as the solution flows through the column. At the low volume rate of flow of approximately 1 ml per min- 6 utc the reaction is essentially complete at the time the solution exits from the bottom of the column through the screen or frit 20 and passes via the conduit 2| to chamber 22 where the oxygen is measured. Thus. no electrical time delays or other complicated electronic or electrical devices are needed in the instrument to measure rate of change of oxygen concentration or to allow for initial surges in the reaction as the reaction is essentially complete before any measurement is made by the oxygen electrode 26. Thus. ofcourse. is another advantage of the simplified flow through system of the present invention.
It should also be noted that inasmuch as the rate of the enzyme-catalyzed reaction involved is somewhate temperature dependent, conventional temperature control means may be required in applications where temperature variations are like.
The embodiments ofthe invention in which an exclusive property or right is claimed are defined as follows: 1. A flow through method for determining the con centration of a component of interest in a sample wherein the detection of the concentration or change therein of a gaseous indicating species following an enzyme-catalyzed reaction is indicative of the concentra tion of the component of interest. said method comprising the steps of:
combining said sample with a carrier solution; causing the combined solution to flow past a quantity of an enzyme selected to catalyze the desired reaction. wherein said enzyme is immobilized in a manner which allows free contact between the components in said combined solution and the enzyme molecules occasioning little or no loss of enzyme thereby; after said reaction is substantially complete. causing the reacted solution to impinge upon a membrane selectively permeable to said gaseous indicating species at an angle with said membrane:
monitoring the concentration of said indicating species diffusing through said membrane;
generating an output indicative of the concentration of said indicating species;
transducing said output into one indicative of the value of the concentration of the component in the sample to be determined; and
removing said solution after contacting said membrane.
2. The method of claim 1, including the step of:
flushing the entire system with an additional amount of said carrier solution thereby regenerating the original conditions prior to the introduction of a subsequent sample.
3. The method of claim 1, including the step of:
controlling the velocity in contacting said immobilized enzyme and said diffusion membrane so that the time interval between the start of the reaction and the measurement of the concentration of the indicating species is fixed.
4. The method of claim I wherein said reacted solution is caused to impinge on said membrane such that said membrane is continually cleansed by said reacted solution.
5. A flow-through chemical analysis apparatus for determining the concentration of a component of interest in a sample wherein the detection of the concentration of an indicating species following an enzyme'catalyzed reaction is indicative of the concentration of the component of interest in the sample, said apparatus com 7 prising:
a first chamber for containing an amount of an immohilized enzyme disposed therein in a manner which allows free contact between said enzyme and a solution flowing therethrough to thereby catalyze said enzyme-catalyzed reaction;
means for introducing a carrier solution into said first chamber;
means for introducing a sample into said solution.
a second chamber for receiving said solution from said first chamber:
sensor means for detecting said indicating species in said solution. said sensor means being separated from the said second chamber by a membrane per meable to said indicating species;
flow means connecting the outlet of said first chamher with said second chamber. in a manner which causes said solution to impinge on said membrane at an angle with said membrane;
means for generating an output from said sensor related to the concentration of said indicating species;
drain means for removing said solution after contacting said membrane; and
transducing means for transducing said output into one indicative of the concentration of the component in the sample sought to be determined.
6. The apparatus of claim 5 wherein said first chamber is in the form of an enclosed packed column.
7. The apparatus as claimed in claim 5 wherein said system is a gravity flow-through system. wherein said reagent-containing solution is fed to the top of said column at an adjustable rate and wherein said second chamber is disposed in a manner which allows it to drain also by gravity.
8. The apparatus as claimed in claim 5 further comprising:
means to control the rate of flow of said solution through said first and said second chambers.
9. The apparatus as claimed in claim 5 wherein said means for supplying said sample is an injection port wherein an accurately determined amount of such sample may be injected into said solution.
10. The apparatus of claim 5 wherein said sensor is an electrochemical detector and said indicating species to be detected is a dissolved gas. said detector having a sensoring electrode disposed opposite and in close proximity to said membrane.
ll. The apparatus as claimed in claim 5 wherein the outlet of flow means is disposed in a manner which causes said solution to impinge on said membrane at right angles to said membrane opposite the location of said sensor.

Claims (11)

1. A FLOW THROUGH METHOD FOR DETERMINING THE CONCENTRATION OF A COMPONENT OF INTEREST IN A SAMPLE WHEREIN THE DETECTION OF THE CONCENTRATION OR CHANGE THEREIN OF A GASEOUS INDICATING SPECIES FOLLOWING AN ENZYME-CATALYZED REACTION IS INDICATIVE OF THE CONCENTRATION OF THE COMPONENT OF INTEREST, SAID METHOD COMPRISING THE STEPS OF: COMBINING SAID SAMPLE WITH A CARRIER SOLUTION, CAUSING THE COMBINED SOLUTION TO FLOW PAST A QUANTITY OF AN ENZYME SELECTED TO CATALYZETHE DESIRED REACTION, WHEREIN SAID ENZYME IS IMMOBILIZED IN A MANNER WHICH ALLOWS FREE CONTACT BETWEEN THE COMPONENTS IN SAID COMBINED SOLUTION AND THE ENZYME MOLECULES OCCASIONING LITTLE OR NO LOSS OF ENZYME THEREBY, AFTER SAID REACTION IS SUBSTANTIALLY COMPLETE, CAUSING THE REACTED SOLUTION TO IMPINGE UPON A MEMBRANE SELECTIVELY PERMEABLE TO SAID GASEOUS INDICATING SPECIES AT AN ANGLE WITH SAID MEMBRANE, MONITORING THE CONCENTRATION OF SAID INDICATING SPECIES DIFFUSING THROUGH SAID MEMBRANE, GENERATING AN OUTPUT INDICATIVE OF THE CONCENTRATION SAID INDICATING SPECIES,
2. The method of claim 1, including the step of: flushing the entire system with an additional amount of said carrier solution thereby regenerating the original conditions prior to the introduction of a subsequent sample.
3. The method of claim 1, including the step of: controlling the velocity in contacting said immobilized enzyme and said diffusion membrane so that the time interval between the start of the reaction and the measurement of the concentration of the indicating species is fixed.
4. The method of claim 1 wherein said reacted solution is caused to impinge on said membrane such that said membrane is continually cleansed by said reacted solution.
5. A flow-through chemical analysis apparatus for determining the concentration of a component of interest in a sample wherein the detection of the concentration of an indicating species following an enzyme-catalyzed reaction is indicative of the concentration of the component of interest in the sample, said apparatus comprising: a first chamber for containing an amount of an immobilized enzyme disposed therein in a manner which allows free contact between said enzyme and a solution flowing therethrough to thereby catalyze said enzyme-catalyzed reaction; means for introducing a carrier solution into said first chamber; means for introducing a sample into said solution; a second chamber for receiving said solution from said first chamber; sensor means for detecting said indicating species in said solution, said sensor means being separated from the said second chamber by a membrane permeable to said indicating species; flow means connecting the outlet of said first chamber with said second chamber, in a manner which causes said solution to impinge on said membrane at an angle with said membrane; means for generating an output from said sensor related to the concentration of said indicating species; drain means for removing said solution after contacting said membrane; and transducing means for transducing said output into one indicative of the concentration of the component in the sample sought to be determined.
6. THE APPARATUS OF CLAIM 5 WHEREIN SAID FIRST CHAMBER IS IN THE FORM OF AN ENCLOSED PACKED COLUMN.
7. The apparatus as claimed in claim 5 wherein said system is a gravity flow-through system, wherein said reagent-containing solution is fed to the top of said column at an adjustable rate and wherein said second chamber is disposed in a manner which allows it to drain also by gravity.
8. The apparatus as claimed in claim 5 further comprising: means to control the rate of flow of said solution through said first and said second chambers.
9. The apparatus as claimed in claim 5 wherein said means for supplying said sample is an injection port wherein an accurately determined amount of such sample may be injected into said solution.
10. The apparatus of claim 5 wherein said sensor is an electrochemical detector and said indicating species to be detected is a dissolved gas, said detector having a sensoring electrode disposed opposite and in close proximity to said membrane.
11. The apparatus as claimed in claim 5 Wherein the outlet of flow means is disposed in a manner which causes said solution to impinge on said membrane at right angles to said membrane opposite the location of said sensor.
US487709A 1974-07-11 1974-07-11 Biological analyzer and method Expired - Lifetime US3919051A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US487709A US3919051A (en) 1974-07-11 1974-07-11 Biological analyzer and method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US487709A US3919051A (en) 1974-07-11 1974-07-11 Biological analyzer and method

Publications (1)

Publication Number Publication Date
US3919051A true US3919051A (en) 1975-11-11

Family

ID=23936815

Family Applications (1)

Application Number Title Priority Date Filing Date
US487709A Expired - Lifetime US3919051A (en) 1974-07-11 1974-07-11 Biological analyzer and method

Country Status (1)

Country Link
US (1) US3919051A (en)

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2393306A1 (en) * 1976-09-20 1978-12-29 Boehringer Mannheim Gmbh METHOD AND APPARATUS FOR THE CONTINUOUS DETERMINATION OF THE CONCENTRATION OF AN ENZYME SUBSTRATE
FR2423778A1 (en) * 1978-04-20 1979-11-16 Siemens Ag METHOD FOR DETERMINING THE CONCENTRATION OF SUGAR AND ELECTROCATALYTIC DETECTOR FOR SUGAR SPECIFIC TO THIS PROCESS
US4229542A (en) * 1975-12-31 1980-10-21 Gambro Ab Apparatus for the measuring of the concentration of low-molecular compounds in complex media
US4311789A (en) * 1975-12-31 1982-01-19 Gambro Ag Method for sampling and measuring the content of a low-molecular weight compound in a complex fluid medium
US5206145A (en) * 1988-05-19 1993-04-27 Thorn Emi Plc Method of measuring the concentration of a substance in a sample solution
US5426032A (en) * 1986-08-13 1995-06-20 Lifescan, Inc. No-wipe whole blood glucose test strip
US5477468A (en) * 1994-01-14 1995-12-19 Project Cd Concentration analyzer
US5605152A (en) * 1994-07-18 1997-02-25 Minimed Inc. Optical glucose sensor
US6458326B1 (en) 1999-11-24 2002-10-01 Home Diagnostics, Inc. Protective test strip platform
US6525330B2 (en) 2001-02-28 2003-02-25 Home Diagnostics, Inc. Method of strip insertion detection
US6541266B2 (en) 2001-02-28 2003-04-01 Home Diagnostics, Inc. Method for determining concentration of an analyte in a test strip
US6562625B2 (en) 2001-02-28 2003-05-13 Home Diagnostics, Inc. Distinguishing test types through spectral analysis
US20030176183A1 (en) * 2001-04-02 2003-09-18 Therasense, Inc. Blood glucose tracking apparatus and methods
US20040249999A1 (en) * 2003-04-04 2004-12-09 Connolly Brian Edmond Method and system for transferring analyte test data
US20080076997A1 (en) * 1998-04-30 2008-03-27 Abbott Diabetes Care, Inc. Analyte monitoring device and methods of use
US7620438B2 (en) 2006-03-31 2009-11-17 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US7766829B2 (en) 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
US7811231B2 (en) 2002-12-31 2010-10-12 Abbott Diabetes Care Inc. Continuous glucose monitoring system and methods of use
US20100312078A1 (en) * 1998-04-30 2010-12-09 Abbott Diabetes Care Inc. Analyte Monitoring Device and Methods of Use
US7920907B2 (en) 2006-06-07 2011-04-05 Abbott Diabetes Care Inc. Analyte monitoring system and method
US7928850B2 (en) 2007-05-08 2011-04-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8066639B2 (en) 2003-06-10 2011-11-29 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
US8103456B2 (en) 2009-01-29 2012-01-24 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US8112240B2 (en) 2005-04-29 2012-02-07 Abbott Diabetes Care Inc. Method and apparatus for providing leak detection in data monitoring and management systems
US8123686B2 (en) 2007-03-01 2012-02-28 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
US8149117B2 (en) 2007-05-08 2012-04-03 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8226891B2 (en) 2006-03-31 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
US8287454B2 (en) 1998-04-30 2012-10-16 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8456301B2 (en) 2007-05-08 2013-06-04 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8612159B2 (en) 1998-04-30 2013-12-17 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8652043B2 (en) 2001-01-02 2014-02-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8665091B2 (en) 2007-05-08 2014-03-04 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8732188B2 (en) 2007-02-18 2014-05-20 Abbott Diabetes Care Inc. Method and system for providing contextual based medication dosage determination
US8771183B2 (en) 2004-02-17 2014-07-08 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
US8930203B2 (en) 2007-02-18 2015-01-06 Abbott Diabetes Care Inc. Multi-function analyte test device and methods therefor
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8993331B2 (en) 2009-08-31 2015-03-31 Abbott Diabetes Care Inc. Analyte monitoring system and methods for managing power and noise
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9226701B2 (en) 2009-04-28 2016-01-05 Abbott Diabetes Care Inc. Error detection in critical repeating data in a wireless sensor system
US9314195B2 (en) 2009-08-31 2016-04-19 Abbott Diabetes Care Inc. Analyte signal processing device and methods
US9320461B2 (en) 2009-09-29 2016-04-26 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
US9980669B2 (en) 2011-11-07 2018-05-29 Abbott Diabetes Care Inc. Analyte monitoring device and methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3542662A (en) * 1967-04-18 1970-11-24 Du Pont Enzyme electrode
US3788950A (en) * 1970-08-05 1974-01-29 Du Pont Enzyme gel and use therefor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3542662A (en) * 1967-04-18 1970-11-24 Du Pont Enzyme electrode
US3788950A (en) * 1970-08-05 1974-01-29 Du Pont Enzyme gel and use therefor

Cited By (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229542A (en) * 1975-12-31 1980-10-21 Gambro Ab Apparatus for the measuring of the concentration of low-molecular compounds in complex media
US4311789A (en) * 1975-12-31 1982-01-19 Gambro Ag Method for sampling and measuring the content of a low-molecular weight compound in a complex fluid medium
FR2393306A1 (en) * 1976-09-20 1978-12-29 Boehringer Mannheim Gmbh METHOD AND APPARATUS FOR THE CONTINUOUS DETERMINATION OF THE CONCENTRATION OF AN ENZYME SUBSTRATE
US4153513A (en) * 1976-09-20 1979-05-08 Boehringer Mannheim Gmbh Method and apparatus for the continuous determination of the concentration of an enzyme substrate
FR2423778A1 (en) * 1978-04-20 1979-11-16 Siemens Ag METHOD FOR DETERMINING THE CONCENTRATION OF SUGAR AND ELECTROCATALYTIC DETECTOR FOR SUGAR SPECIFIC TO THIS PROCESS
US6821483B2 (en) 1986-08-13 2004-11-23 Lifescan, Inc. Reagents test strip with alignment notch
US5426032A (en) * 1986-08-13 1995-06-20 Lifescan, Inc. No-wipe whole blood glucose test strip
US5563042A (en) * 1986-08-13 1996-10-08 Lifescan, Inc. Whole blood glucose test strip
US5843692A (en) * 1986-08-13 1998-12-01 Lifescan, Inc. Automatic initiation of a time interval for measuring glucose concentration in a sample of whole blood
US6268162B1 (en) 1986-08-13 2001-07-31 Lifescan, Inc. Reflectance measurement of analyte concentration with automatic initiation of timing
US6887426B2 (en) 1986-08-13 2005-05-03 Roger Phillips Reagents test strip adapted for receiving an unmeasured sample while in use in an apparatus
US6881550B2 (en) 1986-08-13 2005-04-19 Roger Phillips Method for the determination of glucose employing an apparatus emplaced matrix
US6858401B2 (en) 1986-08-13 2005-02-22 Lifescan, Inc. Minimum procedure system for the determination of analytes
US5206145A (en) * 1988-05-19 1993-04-27 Thorn Emi Plc Method of measuring the concentration of a substance in a sample solution
US5477468A (en) * 1994-01-14 1995-12-19 Project Cd Concentration analyzer
US5605152A (en) * 1994-07-18 1997-02-25 Minimed Inc. Optical glucose sensor
US8612159B2 (en) 1998-04-30 2013-12-17 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8226558B2 (en) 1998-04-30 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US10478108B2 (en) 1998-04-30 2019-11-19 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9326714B2 (en) 1998-04-30 2016-05-03 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9072477B2 (en) 1998-04-30 2015-07-07 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US20080076997A1 (en) * 1998-04-30 2008-03-27 Abbott Diabetes Care, Inc. Analyte monitoring device and methods of use
US9066694B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066697B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9042953B2 (en) 1998-04-30 2015-05-26 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US20100312078A1 (en) * 1998-04-30 2010-12-09 Abbott Diabetes Care Inc. Analyte Monitoring Device and Methods of Use
US7860544B2 (en) 1998-04-30 2010-12-28 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8617071B2 (en) 1998-04-30 2013-12-31 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8622906B2 (en) 1998-04-30 2014-01-07 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US7869853B1 (en) 1998-04-30 2011-01-11 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US7885699B2 (en) 1998-04-30 2011-02-08 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9014773B2 (en) 1998-04-30 2015-04-21 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9011331B2 (en) 1998-04-30 2015-04-21 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8641619B2 (en) 1998-04-30 2014-02-04 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8649841B2 (en) 1998-04-30 2014-02-11 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8880137B2 (en) 1998-04-30 2014-11-04 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8840553B2 (en) 1998-04-30 2014-09-23 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8774887B2 (en) 1998-04-30 2014-07-08 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8744545B2 (en) 1998-04-30 2014-06-03 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8162829B2 (en) 1998-04-30 2012-04-24 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8175673B2 (en) 1998-04-30 2012-05-08 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8177716B2 (en) 1998-04-30 2012-05-15 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8734348B2 (en) 1998-04-30 2014-05-27 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8224413B2 (en) 1998-04-30 2012-07-17 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8226555B2 (en) 1998-04-30 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8738109B2 (en) 1998-04-30 2014-05-27 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8597189B2 (en) 1998-04-30 2013-12-03 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8226557B2 (en) 1998-04-30 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8231532B2 (en) 1998-04-30 2012-07-31 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8734346B2 (en) 1998-04-30 2014-05-27 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8235896B2 (en) 1998-04-30 2012-08-07 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8255031B2 (en) 1998-04-30 2012-08-28 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8260392B2 (en) 1998-04-30 2012-09-04 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8265726B2 (en) 1998-04-30 2012-09-11 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8660627B2 (en) 1998-04-30 2014-02-25 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8275439B2 (en) 1998-04-30 2012-09-25 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8287454B2 (en) 1998-04-30 2012-10-16 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8306598B2 (en) 1998-04-30 2012-11-06 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8346336B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8353829B2 (en) 1998-04-30 2013-01-15 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8357091B2 (en) 1998-04-30 2013-01-22 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8672844B2 (en) 1998-04-30 2014-03-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8366614B2 (en) 1998-04-30 2013-02-05 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8372005B2 (en) 1998-04-30 2013-02-12 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8380273B2 (en) 1998-04-30 2013-02-19 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8391945B2 (en) 1998-04-30 2013-03-05 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8409131B2 (en) 1998-04-30 2013-04-02 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8670815B2 (en) 1998-04-30 2014-03-11 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8273022B2 (en) 1998-04-30 2012-09-25 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8666469B2 (en) 1998-04-30 2014-03-04 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8473021B2 (en) 1998-04-30 2013-06-25 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6979571B2 (en) 1999-11-24 2005-12-27 Home Diagnostics, Inc. Method of using a protective test strip platform for optical meter apparatus
US6458326B1 (en) 1999-11-24 2002-10-01 Home Diagnostics, Inc. Protective test strip platform
US8668645B2 (en) 2001-01-02 2014-03-11 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8652043B2 (en) 2001-01-02 2014-02-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9011332B2 (en) 2001-01-02 2015-04-21 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9498159B2 (en) 2001-01-02 2016-11-22 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9610034B2 (en) 2001-01-02 2017-04-04 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6562625B2 (en) 2001-02-28 2003-05-13 Home Diagnostics, Inc. Distinguishing test types through spectral analysis
US7390665B2 (en) 2001-02-28 2008-06-24 Gilmour Steven B Distinguishing test types through spectral analysis
US6525330B2 (en) 2001-02-28 2003-02-25 Home Diagnostics, Inc. Method of strip insertion detection
US6541266B2 (en) 2001-02-28 2003-04-01 Home Diagnostics, Inc. Method for determining concentration of an analyte in a test strip
US7976778B2 (en) 2001-04-02 2011-07-12 Abbott Diabetes Care Inc. Blood glucose tracking apparatus
US9477811B2 (en) 2001-04-02 2016-10-25 Abbott Diabetes Care Inc. Blood glucose tracking apparatus and methods
US8236242B2 (en) 2001-04-02 2012-08-07 Abbott Diabetes Care Inc. Blood glucose tracking apparatus and methods
US8765059B2 (en) 2001-04-02 2014-07-01 Abbott Diabetes Care Inc. Blood glucose tracking apparatus
US20030176183A1 (en) * 2001-04-02 2003-09-18 Therasense, Inc. Blood glucose tracking apparatus and methods
US7041468B2 (en) 2001-04-02 2006-05-09 Therasense, Inc. Blood glucose tracking apparatus and methods
US8268243B2 (en) 2001-04-02 2012-09-18 Abbott Diabetes Care Inc. Blood glucose tracking apparatus and methods
US8622903B2 (en) 2002-12-31 2014-01-07 Abbott Diabetes Care Inc. Continuous glucose monitoring system and methods of use
US9962091B2 (en) 2002-12-31 2018-05-08 Abbott Diabetes Care Inc. Continuous glucose monitoring system and methods of use
US8187183B2 (en) 2002-12-31 2012-05-29 Abbott Diabetes Care Inc. Continuous glucose monitoring system and methods of use
US10750952B2 (en) 2002-12-31 2020-08-25 Abbott Diabetes Care Inc. Continuous glucose monitoring system and methods of use
US7811231B2 (en) 2002-12-31 2010-10-12 Abbott Diabetes Care Inc. Continuous glucose monitoring system and methods of use
US8437966B2 (en) 2003-04-04 2013-05-07 Abbott Diabetes Care Inc. Method and system for transferring analyte test data
US8682598B2 (en) 2003-04-04 2014-03-25 Abbott Laboratories Method and system for transferring analyte test data
US20040249999A1 (en) * 2003-04-04 2004-12-09 Connolly Brian Edmond Method and system for transferring analyte test data
US8560250B2 (en) 2003-04-04 2013-10-15 Abbott Laboratories Method and system for transferring analyte test data
US8483974B2 (en) 2003-04-04 2013-07-09 Abbott Diabetes Care Inc. Method and system for transferring analyte test data
US7587287B2 (en) 2003-04-04 2009-09-08 Abbott Diabetes Care Inc. Method and system for transferring analyte test data
US9730584B2 (en) 2003-06-10 2017-08-15 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
US8066639B2 (en) 2003-06-10 2011-11-29 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
US8647269B2 (en) 2003-06-10 2014-02-11 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
US8512239B2 (en) 2003-06-10 2013-08-20 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
US8771183B2 (en) 2004-02-17 2014-07-08 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
US8112240B2 (en) 2005-04-29 2012-02-07 Abbott Diabetes Care Inc. Method and apparatus for providing leak detection in data monitoring and management systems
US11399748B2 (en) 2005-11-01 2022-08-02 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9078607B2 (en) 2005-11-01 2015-07-14 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8915850B2 (en) 2005-11-01 2014-12-23 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8920319B2 (en) 2005-11-01 2014-12-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US10952652B2 (en) 2005-11-01 2021-03-23 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US10201301B2 (en) 2005-11-01 2019-02-12 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US10231654B2 (en) 2005-11-01 2019-03-19 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US11363975B2 (en) 2005-11-01 2022-06-21 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US11103165B2 (en) 2005-11-01 2021-08-31 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9326716B2 (en) 2005-11-01 2016-05-03 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US11911151B1 (en) 2005-11-01 2024-02-27 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US11272867B2 (en) 2005-11-01 2022-03-15 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9669162B2 (en) 2005-11-04 2017-06-06 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
US7766829B2 (en) 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
US9323898B2 (en) 2005-11-04 2016-04-26 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
US11538580B2 (en) 2005-11-04 2022-12-27 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
US8585591B2 (en) 2005-11-04 2013-11-19 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
US8226891B2 (en) 2006-03-31 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
US9743863B2 (en) 2006-03-31 2017-08-29 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US7620438B2 (en) 2006-03-31 2009-11-17 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US9039975B2 (en) 2006-03-31 2015-05-26 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
US8933664B2 (en) 2006-03-31 2015-01-13 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US8593109B2 (en) 2006-03-31 2013-11-26 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US9380971B2 (en) 2006-03-31 2016-07-05 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US8597575B2 (en) 2006-03-31 2013-12-03 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
US9625413B2 (en) 2006-03-31 2017-04-18 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
US7920907B2 (en) 2006-06-07 2011-04-05 Abbott Diabetes Care Inc. Analyte monitoring system and method
US8930203B2 (en) 2007-02-18 2015-01-06 Abbott Diabetes Care Inc. Multi-function analyte test device and methods therefor
US8732188B2 (en) 2007-02-18 2014-05-20 Abbott Diabetes Care Inc. Method and system for providing contextual based medication dosage determination
US9801545B2 (en) 2007-03-01 2017-10-31 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
US8123686B2 (en) 2007-03-01 2012-02-28 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
US9095290B2 (en) 2007-03-01 2015-08-04 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
US7928850B2 (en) 2007-05-08 2011-04-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US9035767B2 (en) 2007-05-08 2015-05-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8665091B2 (en) 2007-05-08 2014-03-04 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
US8593287B2 (en) 2007-05-08 2013-11-26 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US9649057B2 (en) 2007-05-08 2017-05-16 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US9000929B2 (en) 2007-05-08 2015-04-07 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US9314198B2 (en) 2007-05-08 2016-04-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US9177456B2 (en) 2007-05-08 2015-11-03 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8362904B2 (en) 2007-05-08 2013-01-29 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8149117B2 (en) 2007-05-08 2012-04-03 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US9949678B2 (en) 2007-05-08 2018-04-24 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
US9574914B2 (en) 2007-05-08 2017-02-21 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
US8461985B2 (en) 2007-05-08 2013-06-11 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8456301B2 (en) 2007-05-08 2013-06-04 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US10178954B2 (en) 2007-05-08 2019-01-15 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8103456B2 (en) 2009-01-29 2012-01-24 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US8676513B2 (en) 2009-01-29 2014-03-18 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US8473220B2 (en) 2009-01-29 2013-06-25 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US9066709B2 (en) 2009-01-29 2015-06-30 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US9226701B2 (en) 2009-04-28 2016-01-05 Abbott Diabetes Care Inc. Error detection in critical repeating data in a wireless sensor system
US9314195B2 (en) 2009-08-31 2016-04-19 Abbott Diabetes Care Inc. Analyte signal processing device and methods
US10429250B2 (en) 2009-08-31 2019-10-01 Abbott Diabetes Care, Inc. Analyte monitoring system and methods for managing power and noise
US11150145B2 (en) 2009-08-31 2021-10-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods for managing power and noise
US9968302B2 (en) 2009-08-31 2018-05-15 Abbott Diabetes Care Inc. Analyte signal processing device and methods
US11635332B2 (en) 2009-08-31 2023-04-25 Abbott Diabetes Care Inc. Analyte monitoring system and methods for managing power and noise
US8993331B2 (en) 2009-08-31 2015-03-31 Abbott Diabetes Care Inc. Analyte monitoring system and methods for managing power and noise
US10349874B2 (en) 2009-09-29 2019-07-16 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
US9750439B2 (en) 2009-09-29 2017-09-05 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
US9320461B2 (en) 2009-09-29 2016-04-26 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
US9980669B2 (en) 2011-11-07 2018-05-29 Abbott Diabetes Care Inc. Analyte monitoring device and methods

Similar Documents

Publication Publication Date Title
US3919051A (en) Biological analyzer and method
US4759828A (en) Glucose electrode and method of determining glucose
US3763422A (en) Method and apparatus for electrochemical analysis of small samples of blood
US4452682A (en) Apparatus for measuring clinical emergency check items of blood
US3539455A (en) Membrane polarographic electrode system and method with electrochemical compensation
US3707455A (en) Measuring system
JPS5841486Y2 (en) Fractionation device
US3672843A (en) Fluid analyzing apparatus
Christian Sequential injection analysis for electrochemical measurements and process analysis
US3591480A (en) Glucose measuring system
Arquint et al. Micromachined analyzers on a silicon chip
WO1983003006A1 (en) Method for measuring ionic concentration utilizing an ion-sensing electrode
US4999305A (en) Apparatus for titration flow injection analysis
US5976465A (en) Apparatus and method for the determination of substances in solution suspension or emulsion by differential pH measurement
US5244561A (en) Process and apparatus for the electrochemical determination of pco2 in blood
US3661010A (en) Fluid sample analyzing apparatus
Park et al. A simple method for the estimation of plasma ammonia using an ion specific electrode.
Meyerhoff et al. Polymer-membrane electrode-based potentiometric sensing of ammonia and carbon dioxide in physiological fluids.
US3768973A (en) Energy compensated enthalpimeter for process analysis
Wilson Catalytic Determination of Molybdate with the Perborate-Iodide Reaction.
US3930957A (en) Apparatus and method for biological analysis
US4798803A (en) Method for titration flow injection analysis
Pungor et al. Automatic Electrochemical Analysis: Part 2
Herman et al. Serum carbon dioxide determination using a carbonate ion-selective membrane electrode
JPS6325301B2 (en)